July 28th 2025
Pooled data from early-phase trials suggest JSKN003 is tolerable and active in patients with heavily pretreated HER2-positive disease.
SABCS 2010: Obesity Ups Risk of Recurrence for Some Women With HER2-Negative Breast Cancer
March 4th 2011Being obese at the time operable breast cancer is diagnosed is associated with inferior outcomes in women with estrogen receptor (ER) or progesterone receptor (PR)positive, HER2-negative breast cancer.